


How is Vaccine Safety Monitored in the U.S.?

Vaccine safety monitoring systems in the U.S.

The success of vaccination programs depends not only on vaccines' effectiveness, but also on their safety. Because vaccines are given to millions of healthy people each year, they are held to a very high standard and are continuously monitored for safety.

The U.S. has one of the most advanced systems in the world for tracking vaccine safety. This includes a coordinated and overlapping approach using state-of-the-art technologies and systems working together. Each of the "gears", or systems, supplies a different type of data for researchers to analyze. Together, they work as a well-oiled machine to help provide a full, overall picture of vaccine safety in the U.S. Each of these systems is detailed below.



Vaccine Adverse Event Reporting System (VAERS)

VAERS is used by the FDA and the CDC to collect reports of adverse events (possible side effects) that happen after vaccination. The system relies on individuals to send in reports of adverse health events following vaccination – meaning anyone can and should report adverse events to VAERS. Scientists monitor VAERS reports to identify adverse events that need to be studied further. Reports of adverse events that are unexpected, appear to happen more often than expected, or have unusual patterns are followed up with additional research to determine whether the adverse event that is happening after vaccination is occurring more often than would be expected without vaccination.

When safety signals are identified through VAERS, other safety monitoring systems are engaged to further study the issue. While VAERS may help identify safety issues, other safety monitoring systems, like VSD, allow us to determine if a vaccine is associated with a certain outcome and the rate at which it occurs.

What are the strengths of VAERS?

- Anyone can submit reports to VAERS (passive surveillance system)
- Serves as an early warning/hypothesis-generating system. For example, in early 2020, reports to VAERS indicated a need for further study of mRNA-based COVID-19 vaccines and a possible increased risk of severe allergic reactions following vaccination. Additional investigation indicated that these reactions are quite rare, happening in less than one in 200,000 vaccinated individuals.

What are the limitations of VAERS?

- Cannot determine if a vaccine caused the reported adverse event
- May lack details or contain errors
- Does not allow for a comparison of rates of adverse events in those who did and did not receive a vaccine (no control group)

Vaccine Safety Datalink (VSD)

The VSD is a network of thirteen managed care sites across the U.S. with a combined patient population of more than 24 million people. The VSD is used to determine if possible side effects identified using VAERS are actually related to vaccination, and it can identify safety signals using nearly real-time monitoring. Each week, VSD evaluates particular health-related outcomes that may be associated with vaccination and compares it to the expected number of outcomes in a comparison group.

What are the benefits of VSD?

- Conduct timely vaccine safety studies, including assessments of rare adverse events and longitudinal studies involving prolonged follow-up of individual patients
- Use of a control group – allowing for the comparison of adverse events in those who did and did not receive a vaccine (can compare vaccinated to unvaccinated)

What are the limitations of VSD?

- May not have enough patients to detect extremely rare adverse events
- May not capture vaccine administration data outside of the health system
- Cannot determine if an association between an adverse event and vaccination is causal

Why is it important to monitor vaccines post-licensure?

Monitoring a vaccine after it is licensed or authorized helps ensure that vaccines continue to be safe and effective and the benefits continue to outweigh the risks.

Clinical trials typically involve thousands of participants. However, even in large clinical trials, they generally lack adequate sample sizes to identify rare adverse events - an event that may occur after 1 in 100,000 or 1 in a million doses administered. Post-licensure safety studies help validate safety data from clinical trials and may detect adverse events that were not picked up in clinical trials.

Inclusion in clinical trials may exclude specific vulnerable sub-populations, such as pregnant women or immunocompromised adults, for whom a vaccine may be indicated. Studies done post-licensure monitor the safety, effectiveness and benefits of vaccination in these populations.

Clinical Immunization Safety Assessment Project (CISA)

The CISA Project is a national network of vaccine safety experts from the CDC, seven medical research centers, and other partners. The project addresses vaccine safety issues, conducts high quality research, and assesses complex clinical adverse events following vaccination through active surveillance.

What are the benefits of the CISA project?

- Serves as a vaccine safety resource for U.S. health care providers and assist CDC and its partners in evaluating emerging vaccine safety issues
- Can implement prospective, multi-site clinical studies with hundreds of subjects and has the ability to recruit controls
- Can assess vaccine safety in sub-populations (e.g. pregnant women, infants, and children)
- Receives detailed clinical data on patients and can collect biological samples from patients

What are the limitations of the CISA project?

- Small sample sizes may limit CISA's ability to study rare adverse events
- Clinical trials can be labor and resource intensive, and it can be challenging to recruit and retain subjects

Post-licensure Rapid Immunization Safety Monitoring System (PRISM)

PRISM is the largest vaccine safety surveillance system in the U.S., with access to information for over 190 million people. PRISM uses a database of health insurance claims to identify and evaluate possible safety issues for licensed vaccines.

What are the strengths of PRISM?

- Covers hundreds of millions of individuals, which allows for the system to identify and analyze rare health outcomes that would otherwise be difficult to assess
- Linked to some state-wide registries and birth registries - allowing for more complete vaccine exposure data
- Access to denominator data for vaccine exposure, which allows the FDA to estimate a measure of association between a vaccine and adverse events

What are the limitations of PRISM?

- There is a lag in time for accessing the PRISM data
- Medicare population is not as well represented in PRISM
- May not be representative of those without insurance coverage

V-safe

V-safe, a new active surveillance program in the U.S., is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after an individual receives a COVID-19 or mpox (Monkeypox) vaccine.

What are the strengths of V-safe?

- Anyone can enroll in V-safe
- Another way to quickly validate safety data from clinical trials or identify potential safety issues
- Regular reminders to complete a survey help to capture more safety data
- CDC will follow-up with participants and submit VAERS reports, as needed

What are the limitations of V-safe?

- May not properly represent older populations and socioeconomically disadvantaged populations who might not have access to electronic devices to complete web-based surveys and may be subject to under-reporting

Additional research and testing

There are a number of other organizations involved in assessing the safety of vaccines. The Department of Defense (DoD), the U.S. Department of Veterans Affairs (VA), and the Indian Health Service (IHS) have systems to monitor vaccine safety and do vaccine safety research. The National Institutes of Health (NIH) and the Office of Infectious Disease and HIV/AIDS Policy (OIDP) also support ongoing research on vaccines and vaccine safety.

Vaccine-related data from other countries

The U.S. also monitors and assesses high-quality data on vaccine safety and effectiveness out of other countries. For example, the U.K. and Qatar have large national healthcare-related datasets that allow for scientists and researchers to evaluate vaccine safety and compare large groups of people who have and have not been vaccinated and control for various factors and health outcomes. These data can validate U.S. safety monitoring results and provide insight on what signals the U.S. vaccine safety monitoring systems should be assessing and monitoring.

References

1. Bok K. Overview of the U.S. Vaccine Safety Surveillance System & Ongoing Scientific Activities to Monitor Maternal Vaccine Safety. Lecture presented on: September 9, 2014.
2. <https://www.cdc.gov/vaccines/hcp/conversations/ensuring-safe-vaccines.html>
3. <https://www.cdc.gov/vaccinesafety/pdf/iso-factsheet1.pdf>
4. <https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Ensuring-the-Safety-of-Vaccines-in-the-United-States.pdf>
5. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hall E., Wodi A.P., Hamborsky J., et al., eds. 14th ed. Washington, D.C. Public Health Foundation, 2021.
6. <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html>
7. <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html>
8. <https://www.fda.gov/vaccines-blood-biologics/workshops-meetings-conferences-biologics/public-workshop-sentinel-post-licensure-rapid-immunization-safety-monitoring-prism-system>
9. Shimabukuro T. Enhanced safety monitoring for COVID-19 vaccines in early phase vaccination. Lecture presented on: September 22, 2020.